Healthcare / Drug Manufacturers - Specialty & GenericStockholm
$1.55
+0.13 (+9.51%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-26.6M · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$47M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-29.7%
↓Gross Margin
43.5%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+135.2%
FCF CAGR
—
FCF margin
-72.3%
FCF / Net income
1.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $36.8M · net income $-15.4M · FCF $-26.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $36.8M | $36.8M | $10.3M | $5.5M | $2.8M |
| Net Income | $-15.4M | $-15.4M | $-19.4M | $-14.7M | $-5.6M |
| EBITDA | $-12.1M | $-12.1M | $-18.2M | $-13.7M | — |
| EPS | -0.64 | -0.64 | -1.00 | -0.75 | — |
| Gross Margin | 43.5% | 43.5% | 38.5% | 28.4% | 16.3% |
| Operating Margin | -39.3% | -39.3% | -176.5% | -224.4% | — |
| Net Margin | -41.8% | -41.8% | -189.3% | -265.9% | -196.4% |
| Balance Sheet | |||||
| Current Ratio | 1.11 | 1.11 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-26.6M | $-26.6M | $-24.1M | $-39.4M | — |
| Returns | |||||
| ROE | -29.7% | -29.7% | -39.3% | -21.3% | -14.4% |
| Valuation | |||||
| P/B | 0.73 | 0.73 | 1.51 | 1.20 | — |
| Growth & Yield | |||||
| Revenue Growth | 258.7% | 258.7% | 86.1% | 95.0% | — |
| EPS Growth | 36.2% | 36.2% | -32.5% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-39.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.00 → -0.64
Residual
-39.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.